People taking retatrutide, a drug being developed by Eli Lilly, lost an average of more than 70 pounds, or 28.3% of their bodyweight, over the course of 80 weeks, according to the company's preliminary report of clinical trial results
* Excludes Quebec, Nova Scotia, Nunavut and the Northwest Territories The information presented here is for educational purposes and is not meant to replace the advice from your medical professional
Start metformin at a low dose (500 mg once or twice daily) and titrate slowly at intervals set by your prescriber, commonly about every 4 weeks to minimize GI upset
This documentation enables retrospective analysis if you notice any unexpected changes in your data patterns
In December 2024, the TRIUMPH-4 Phase 3 trial results were announced, showing that participants taking retatrutide 12 mg achieved an average weight loss of 71.8 pounds or 28.7% of body weight over 68 weeks